Bernstein sets USD 365 target for Natera stock after Q2 growth

Published on 10/16/2026 at 10:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera posted USD 752.75 million in second-quarter revenue, up 37.70 percent year over year. Natera stock trades at EUR 361.00 on October 16, 2026.

Analyst views and operating scale

Bernstein maintained a Buy rating and set a USD 365.00 target on October 12, 2026.
Second-quarter revenue reached USD 752.75 million, up 37.70 percent year over year.
Natera stock trades at EUR 361.00 at 10:32 a.m. CEST at Lang & Schwarz on October 16, 2026.
Market capitalization stood at USD 58.3 billion as of October 15, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) stock trades at EUR 361.00 at Lang & Schwarz on October 16, 2026, while Bernstein maintained a Buy rating and set a USD 365.00 price target on October 12. The latest reported quarter also showed USD 752.75 million in revenue and a GAAP net loss of USD 66.97 million, according to Markets Insider.

Bernstein holds at USD 365

Markets Insider reported that Bernstein analyst Eve Burstein maintained the Buy rating and set the USD 365.00 target on October 12, 2026. The same report cited Natera revenue of USD 752.75 million for the quarter ended June 30, compared with USD 546.60 million a year earlier.

That revenue increase was paired with a smaller GAAP loss. Natera reported a USD 66.97 million GAAP net loss for the latest quarter, compared with a USD 100.94 million loss in the prior-year quarter, giving investors a clearer operating comparison than the headline rating alone.

Three recent milestones carry figures

Natera reported USD 752.75 million in second-quarter revenue on August 6, 2026, Bernstein set a USD 365.00 target on October 12, 2026, and the companys market value reached USD 58.3 billion as of October 15, 2026.

What does the revenue increase mean?

The 37.70 percent year-over-year revenue gain shows the scale of Nateras expansion, but the company remained loss-making on a GAAP basis. MarketBeat said revenue exceeded the USD 661.24 million consensus estimate, while the adjusted loss of USD 0.47 per share was narrower than the USD 0.49 consensus loss.

Analyst expectations remain spread across a wide range. MarketBeat reported a consensus target of USD 363.93 on October 14, 2026, while Citigroup had raised its target from USD 365.00 to USD 480.00 on October 6 and Barclays had lifted its target from USD 340.00 to USD 475.00 on October 7.

Stock valuation remains substantial

The primary listing is Nasdaq, where Natera was last quoted at USD 404.79 on October 15, 2026 at 4:00 p.m. ET. The same market-data snapshot put the 52-week range at USD 178.01 to USD 437.41, leaving the latest primary-market quote USD 32.62 below the yearly high.

Market view and price

Natera combines reproductive health, oncology and organ-health testing through its cell-free DNA platform. Its investor-relations page says the company has more than 400 peer-reviewed publications supporting its tests.

Natera stock was trading at EUR 361.00 at Lang & Schwarz on October 16, 2026 at 10:32 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Natera stock.